Eagle Health Investments LP - 4D MOLECULAR THERAPEUTICS IN ownership

4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 91 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Eagle Health Investments LP ownership history of 4D MOLECULAR THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$5,574,607
-29.6%
437,9110.0%1.23%
-17.0%
Q2 2023$7,913,052
+5.1%
437,9110.0%1.48%
+1.0%
Q1 2023$7,527,690
-22.6%
437,9110.0%1.46%
-34.7%
Q4 2022$9,726,003
+228.4%
437,911
+18.9%
2.24%
+230.0%
Q3 2022$2,962,000
+62.3%
368,411
+40.9%
0.68%
+60.0%
Q2 2022$1,825,000
-8.6%
261,423
+97.9%
0.42%
-13.6%
Q1 2022$1,997,000
-31.1%
132,0900.0%0.49%
-30.3%
Q4 2021$2,898,000
+88.2%
132,090
+131.4%
0.71%
+44.7%
Q3 2021$1,540,000
+12.0%
57,0900.0%0.49%
+3.4%
Q2 2021$1,375,000
-36.6%
57,090
+14.2%
0.47%
-44.5%
Q1 2021$2,169,000
+4.6%
50,0000.0%0.85%
-35.8%
Q4 2020$2,073,00050,0001.33%
Other shareholders
4D MOLECULAR THERAPEUTICS IN shareholders Q2 2022
NameSharesValueWeighting ↓
VR Adviser, LLC 3,000,000$38,190,0004.02%
Casdin Capital, LLC 1,033,811$13,160,4141.46%
BVF INC/IL 4,007,413$51,014,3671.38%
Deep Track Capital, LP 2,778,107$35,365,3021.36%
Opaleye Management Inc. 308,500$3,927,2051.28%
Eagle Health Investments LP 437,911$5,574,6071.23%
Novo Holdings A/S 1,200,000$15,276,0001.13%
RA Capital Management 4,163,211$52,997,6761.04%
VIKING GLOBAL INVESTORS LP 4,787,914$60,950,1450.25%
HighVista Strategies LLC 33,419$425,4240.20%
View complete list of 4D MOLECULAR THERAPEUTICS IN shareholders